US10131907 — Glycoconjugates of RNA interference agents
Method of Use · Assigned to Alnylam Pharmaceuticals Inc · Expires 2028-08-24 · 2y remaining
What this patent protects
This patent protects methods for delivering RNA interference agents to cells, particularly hepatocytes, using glycoconjugates.
USPTO Abstract
The present invention relates to agents, compositions and methods for inhibiting the expression of a target gene, comprising an RNAi agent bearing at least one galactosyl moiety. These are useful for delivering the gene expression inhibiting activity to cells, particularly hepatocytes, and more particularly in therapeutic applications.
Drugs covered by this patent
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-2995 |
— | lumasiran-sodium |
U-4413 |
— | inclisiran-sodium |
U-3396 |
— | vutrisiran-sodium |
U-2672 |
— | givosiran-sodium |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.